to-BBB announces collaboration with Genzyme on brain delivery of biologics for neurodegenerative diseases
The disease modifying properties of biological drugs, like peptides, enzymes and antibodies have become well established in the last decades as important medicines. The treatment of brain diseases with these modern treatments is unfortunately hampered by the inability of such drugs to easily pass the blood-brain barrier (BBB).
to-BBB’s G-Technology is designed to transport different classes of drugs across the blood-brain barrier by formulating these drugs into proprietary glutathione coated liposomes. The company has shown proof of concept in different disease models and Genzyme will now evaluate the technology in its disease models.
Geoff McDonough, senior vice president at Genzyme says, "This collaboration will explore an essential component of our work to deliver therapies to the brain, and could further our commitment to patients with neuronopathic disease."
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous